Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

<table class="algorithm-group"><tr><td><table class="algorithm" id="alg2"><tr><td>(i)</td><td> Patients with M0CRPC with PSA doubling times ≤10 months are those that can benefit most from second-generation antiandrogens</td></tr><tr><td>(ii)</td><td>In M0CRPC patients with PSA doubling times &gt;10 months, we recommend watchful waiting and two to three yearly determinations of PSA levels and a multidisciplinary approach to establish therapy</td></tr><tr><td>(iii)</td><td>A comprehensive assessment with validated geriatric and comorbidity burden scales should precede the establishment of therapy in patients with M0CRPC</td></tr><tr><td>(iv)</td><td>Extending metastasis-free survival, prospectively associated with increased overall survival, is considered a suitable therapeutic goal in the routine management of patients with M0CRPC</td></tr></table></td></tr></table>

<div> Recommendations regarding the treatment of M0CRPC.</div>

Prostate Cancer

alg2

Box 2

Box 2: Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 

Box 2 | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 